Table 4.

Correlation between OS and nine-gene prognostic signature of PDAC patients

Variables	Patients (n=112)	MST (days)	Crude HR (95% CI)	Crude P-value	Adjusted HR (95% CI)	Adjusted P-value*
High risk	56	458	1		1
Low risk	56	603	0.470 (0.287–0.770)	0.003	0.513 (0.285–0.924)	0.026

Note:

^*Adjusted for pathologic stage, histologic grade, radical resection, radiation therapy and targeted molecular therapy.

Abbreviations: OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; MST, median survival time; HR, hazard ratio; CI, confidence interval.